{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:33:54Z","timestamp":1786988034961,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejca.2022.04.019","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T06:24:06Z","timestamp":1652768646000},"page":"64-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies"],"prefix":"10.1016","volume":"170","author":[{"given":"Daniele","family":"Rossini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco M.","family":"Germani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-8138","authenticated-orcid":false,"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Dell'Aquila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Borelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Allegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Maddalena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Randon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Marmorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zaniboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Buonadonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7242-4396","authenticated-orcid":false,"given":"Alessandra","family":"Boccaccino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7713-4005","authenticated-orcid":false,"given":"Veronica","family":"Conca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Antoniotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Passardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-8989","authenticated-orcid":false,"given":"Gianluca","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.04.019_bib1","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon cancer, version 2.2021, NCCN clinical practice guidelines in Oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.ejca.2022.04.019_bib3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nrclinonc.2015.129","article-title":"First-line chemotherapy for mCRC\u2014a review and evidence-based algorithm","volume":"12","author":"Cremolini","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib4","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.019_bib5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","volume":"21","author":"Cremolini","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01225","article-title":"Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer","author":"Cremolini","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib7","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/annonc\/mdv012","article-title":"Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial","volume":"26","author":"Masi","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib8","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41416-020-01089-9","article-title":"Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO","volume":"124","author":"Rossini","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2022.04.019_bib11","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","article-title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial","volume":"14","author":"Cunningham","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.4002","article-title":"First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: the PANDA study","author":"Lonardi","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib13","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.019_bib14","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-21-0557","article-title":"FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H\/dMMR advanced unresectable or metastatic colorectal carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.04.019_bib15","doi-asserted-by":"crossref","first-page":"100145","DOI":"10.1016\/j.esmoop.2021.100145","article-title":"The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer","volume":"6","author":"Trullas","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2022.04.019_bib16","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600e-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.019_bib17","article-title":"FDA approves encorafenib for colorectal cancer","year":"2020","journal-title":"National Cancer Institute"},{"key":"10.1016\/j.ejca.2022.04.019_bib18","doi-asserted-by":"crossref","first-page":"100031","DOI":"10.1016\/j.esmoop.2020.100031","article-title":"The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy","volume":"6","author":"Trullas","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2022.04.019_bib19","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib20","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib21","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.019_bib22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.04.019_bib24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in asian patients with previously treated metastatic colorectal cancer: the TERRA study","volume":"36","author":"Xu","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib25","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/annonc\/mdy038","article-title":"Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review","volume":"29","author":"Arnold","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00280-018-3713-6","article-title":"Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?","volume":"83","author":"K\u00f6stek","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2022.04.019_bib27","doi-asserted-by":"crossref","first-page":"iv37","DOI":"10.1093\/annonc\/mdz155.138","article-title":"Chemotherapy rechallenge or reintroduction, regorafenib, and TAS-102 for metastatic pretreated colorectal cancer patients: a propensity score analysis of treatment beyond the second line (PROSERpINA Study)","volume":"30","author":"Calegari","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib28","first-page":"135","article-title":"Clinical practice patterns in chemotherapeutic treatment regimens for metastatic colorectal cancer","volume":"15","author":"McLean","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ejca.2022.04.019_bib29","first-page":"372","article-title":"Treatment of patients with metastatic colorectal cancer in a real-world scenario: probability of receiving second and further lines of therapy and description of clinical benefit","volume":"16","author":"Tampellini","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ejca.2022.04.019_bib30","doi-asserted-by":"crossref","first-page":"e748","DOI":"10.3747\/co.26.4861","article-title":"A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada","volume":"26","author":"Kennecke","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JOP.2010.000072","article-title":"Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical Oncology practice","volume":"6","author":"Hess","year":"2010","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.ejca.2022.04.019_bib32","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1148\/rg.317115050","article-title":"Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0","volume":"31","author":"Chalian","year":"2011","journal-title":"Radiographics"},{"key":"10.1016\/j.ejca.2022.04.019_bib33","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.019_bib34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","article-title":"Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial","volume":"23","author":"Fakih","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/annonc\/mdt547","article-title":"Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation","volume":"25","author":"Pietrantonio","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib36","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/annonc\/mdy197","article-title":"Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced\u00a0colorectal cancer patients bearing MGMT methylation","volume":"29","author":"Morano","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib37","doi-asserted-by":"crossref","first-page":"S530","DOI":"10.1016\/j.annonc.2021.08.905","article-title":"383O MAYA trial: temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC)","volume":"32","author":"Pietrantonio","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.019_bib38","doi-asserted-by":"crossref","first-page":"TPS2659","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS2659","article-title":"Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: the ARETHUSA trial","volume":"37","author":"Siena","year":"2019","journal-title":"J Clin\u00a0Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922002295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922002295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:36:30Z","timestamp":1760733390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922002295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":38,"alternative-id":["S0959804922002295"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.04.019","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}